Using a continuous glucose monitor to help young adults manage type 2 diabetes.
Official title: CAPAZ-2D: Continuous Glucose Monitoring to Augment and Personalize Self-Management of Type 2 Diabetes in Hispanic/Latinx Young Adults
Run by San Diego State University · NCT07065721 · Data updated 2026-11-12
This 30-day program gives young adults with type 2 diabetes a wearable continuous glucose monitor to try and see if real-time glucose data helps them notice patterns and manage their blood sugar and daily habits.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | San Diego State University Academic / other |
| Locations | 1 site (San Diego, California) |
| Status | Recruiting |
| Started | October 2, 2025 |
| Main results expected | December 1, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | November 9, 2026 |
| Trial ID | NCT07065721 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are 18–45 years old, diagnosed with type 2 diabetes within the past five years, have no prior wearable CGM experience, own a compatible smartphone, and are fluent in English or Spanish.
✕Probably not a fit
People with long-standing diabetes beyond five years, prior CGM experience, no compatible smartphone, pregnancy or recent postpartum status, or severe mental illness are unlikely to be eligible or to benefit from this pilot.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This community-engaged, mixed-methods pilot enrolls young adults (ages 18-45) with recent-onset type 2 diabetes to wear a continuous glucose monitor (CGM) for 30 days. The study collects quantitative data from the CGM and linked behavioral trackers (for example, step counts and dietary logs) alongside surveys of self-management behaviors. After the wear period, researchers conduct qualitative interviews to identify barriers and facilitators to CGM use and participants' changes in awareness of glucose patterns. Findings will inform the design of a CGM-based self-management intervention tailored to young adults.
Why it matters
Potential benefit: If successful, this approach could help young adults better recognize glucose patterns, improve daily diabetes self-care, and reduce average blood glucose levels.
How similar studies have gone: Previous studies in adults with type 2 diabetes have shown CGMs can improve glycemic awareness and some outcomes, but using CGMs specifically in young adults with integrated behavioral data and qualitative input is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult 18-45 years of age * diagnosis of type 2 diabetes in the last 5 years, as evidenced in the electronic medical record * no prior use or experience with wearable CGMs * possession of a smart phone that is compatible with Dexcom CGM sensors (nearly all smartphones are compatible) and willing to download and utilize the Dexcom CGM app * fluency in English or Spanish Exclusion Criteria: * severe mental illness (e.g., psychosis, suicidal ideation); * pregnancy or \<6 months postpartum
Where it's running
-
Scripps Health
San Diego, California, United States Recruiting
Study contacts
- Principal investigator: Jessica L McCurley, PhD MPH — San Diego State University
- Study coordinator: Jessica L McCurley, PhD, MPH
- Email: jlmccurley@sdsu.edu
- Phone: 619-594-2132
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lifestyle change program to help type 2 diabetes go into remission in Pakistan
This study tests whether a structured, plant-predominant lifestyle program can put adults with type 2 diabetes in Lahore, Pakistan into remission for the first six months.
-
Colchicine for preventing cardiovascular disease in adults with type 2 diabetes
A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.
-
MWN105 injection in overweight or obese adults you may join
This early-phase trial tests whether MWN105 is safe and tolerable in overweight or obese adults in China, using a placebo comparison.
-
MWN109 tablets in adults with type 2 diabetes mellitus
A phase 2 trial tests MWN109 tablets versus placebo (and against active control semaglutide) to see if the medicine helps adults with type 2 diabetes lower their blood sugar.
-
Brain-heart axis in adults with type 2 diabetes
This study tests how brain activity and heart regulation relate to metabolic status in adults with type 2 diabetes to understand cognitive and functional health.
-
Digital dietary help for people on GLP-1 therapy to reach better blood sugar and weight
This trial tests whether adding a digital dietary program (NutriSteppe) to usual care helps adults on GLP-1 medications see better blood sugar control and weight results.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.